Study raises hope for effective malaria vaccine

Tübingen study raises hope for effective malaria vaccine
The vaccine is injected into the subject at the same time as they receive an antimalarial drug. Credit: Universität Tübingen/Paul Mehnert

At the University Hospital of Tübingen, a clinical trial led by Prof. Dr. Peter Kremsner, Director of the Institute of Tropical Medicine, Travel Medicine and Human Parasitology and Dr. Rolf Fendel, Research Group Leader at the Institute of Tropical Medicine partnered with the German Center for Infection Research (DZIF), was able to show that the vaccine, Sanaria PfSPZ-CVac, which is being developed in Tübingen together with the biotechnology company Sanaria Inc., provides 77 percent cross-strain protection against malaria parasites.

Sanaria PfSPZ-CVac is a live vaccine consisting of infectious Plasmodium falciparum (Pf) parasites that are injected into the subject at the same time as they receive an antimalarial drug. The parasites quickly enter the liver where they develop and multiply for 6 days, and then emerge into the blood As soon as the parasites leave the liver, the drug kills them immediately. Thus, the immune system of the vaccinated subject is primed against many parasite proteins and becomes highly effective at killing malaria parasites in the liver to block infection and prevent disease.

"With this study, we have reached a new important milestone in the development of an effective malaria vaccine. With only three immunizations over four weeks, we achieved very good protection against malaria," explains Prof. Peter Kremsner, who has helped to advance the malaria research field at the DZIF since its inception. His team was able to develop a new immunization regimen that significantly reduces vaccine administration compared to previous studies. The number of visits required by a subject for complete immunization has been reduced from 13 to three. Importantly, the team showed that vaccination with parasites from Africa could protect against genetically diverse parasites from South America.

Proof of efficacy was provided using the controlled human malaria infection (challenge) regimen developed by the Tübingen and Sanaria teams. Here, the were infected with parasites after immunization. If immunization against the parasites was successful, the parasites would be specifically killed by the . If the immune protection is incomplete and the parasites multiply, the test subjects are treated before any symptoms of disease appear. Ten of 13 subjects vaccinated in this study were completely immune to the infection.

"The produces a high level of different antibodies and in the body that can recognize both the injected parasites and antigens of the subsequent liver stage. These antibodies and cells contribute to the strong protective immunity," explains Dr. Rolf Fendel.

With an estimated 229 million infections and 409,000 deaths worldwide in 2019, malaria is one of the world's most important and dangerous infectious diseases. It is caused by transmitted to humans through the bites of infected female mosquitoes. Children under the age of five are the most vulnerable group affected by malaria, accounting for 67 percent (274,000) of all malaria deaths worldwide in 2019.

Explore further

First clinical trial with genetically modified malaria vaccine completed

More information: Zita Sulyok et al, Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial, Nature Communications (2021). DOI: 10.1038/s41467-021-22740-w
Journal information: Nature Communications

Provided by German Center for Infection Research
Citation: Study raises hope for effective malaria vaccine (2021, May 5) retrieved 3 October 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors